Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
gov/books/NBK259191/PubMed PMID: 25506972
suggesting rolapitant is a viable clinical candidate for this indication
Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome
Chemical Name: 6-(2-(tert-butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline
4]triazin-7-yl)cyclohexanecarboxylic acid
CPI-455 - KDM5 Demethylases Inhibitor. CAS# 1628208-23-0 Catalog No.:M60326-2S gov/books/NBK259191/PubMed PMID: 25506972CPI 455, CAS No. 1628208 23 0, is a potent and selective inhibitor of KDM5 demethylases which reduces survival of drug tolerant cancer cells. CPI 455 mediated KDM5 inhibition, elevated global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents. Pretreatment of cancer cells with a KDM5 specific inhibitor results in the ablation of a
US$ 60.89
US$ 14.99
US$ 19.81
US$ 18.81
US$ 10.00
US$ 12.00
US$ 38.49